Source link : https://www.newshealth.biz/health-news/long-term-dupilumab-for-ad-evaluated-in-cohort-study/
TOPLINE: Dupilumab remained effective in most patients with atopic dermatitis (AD) up to 5 years, although nearly a quarter of patients in the cohort study discontinued treatment because of adverse events (AEs) and/or ineffectiveness, researchers report. METHODOLOGY: A prospective multicenter cohort study evaluated 1286 patients with AD from the BioDay registry (130 children, 1025 adults […]
Author : News Health
Publish date : 2024-08-08 08:52:20
Copyright for syndicated content belongs to the linked Source.
in Health